Glaxo respiratory approvals could bump production at Advair plant; Pharma steps up in Indian HIV/AIDS drug shortage;

@FiercePharma: Top-read news this weekend: Bayer resolves 200 Trasylol lawsuits. Article | Follow @FiercePharma

@EricPFierce: EU official says hunting wild boar may be spreading African swine fever. Wants it stopped. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Novartis employee pleads guilty to bribery in Poland. Story | Follow @CarlyHFierce

> GlaxoSmithKline's ($GSK) recent FDA approvals could spell a production increase at its Zebulon, NC, plant. More

> Amid dwindling supply in India, Indian companies and global health groups have ramped up efforts to provide tenofovir/lamivudine tablets for the country's free HIV/AIDS drug program. Report

> Healthcare group BTG plans to start selling two of its oncology treatments directly to 11 European countries, beginning next April. More

> New analysis of Celgene's ($CELG) ESTEEM 2 trial demonstrated that more than 70% of patients who received treatment with psoriasis drug Otezla twice-daily after 16 weeks achieved clinically meaningful improvement. Report

> Alexion Pharmaceuticals ($ALXN) has named Leonard Bell the chairman of its board. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Deerfield bets up to $125M on nuclear materials used in imaging. Article | Follow @FierceMedDev

@VarunSaxena2: Report warns of cyberattacks against medical devices to extort money. More | Follow @VarunSaxena2

[No ads for editors]

@EmilyWFierce: Device from Bay Area startup detects microRNA in blood to screen for dozens of cancers. Story via Wired | Follow @EmilyWFierce

@MichaelGFierce: With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. FierceDrugDelivery story | Follow @MichaelGFierce

> PAD patients gain another treatment option as the FDA approves its first drug-coated balloon. Story

> Harvard scientists develop super-repellent coating technology for commonly used devices. Report

Biotech News

@FierceBiotech: 2014's most successful biotech IPOs. Special report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Gilead wins FDA approval for its hep C combo pill, a blockbuster in the making. Article | Follow @JohnCFierce

@DamianFierce: And finally, wins FDA approval for Harvoni. Release | Follow @DamianFierce

@EmilyMFierce: What It's Like to Carry Your Nobel Prize through Airport Security. Article from Scientific American | Follow @EmilyMFierce

> Smith & Nephew hit by setback as PhIII regenerative med study flops. Story

> Pfizer nabs a fast FDA review for breast cancer pipeline star palbociclib. More

> MGH investigator Tanzi says breakthrough will 'revolutionize' Alzheimer's R&D. Article

CRO News

> Catalent reaches out to lung cancer patients with research agreement. Item

> Covance and Novartis team up with eyes on Big Data. Article

> Parexel expands in the U.K. after an eClinical buyout. Story

> Clinipace raises $4M after staging 5 buyouts in 5 years. More

> With help from Charles River, AstraZeneca expands its respiratory pipeline. Report

Biotech IT News

> Merck's VC unit invests in data security business. More

> ISB teams with Google for NCI Cancer Genomics Cloud project. Report

> NIH turns on Big Data funding faucet. Story

> Merck and Pfizer join Accenture's Life Sciences Cloud Coalition. News

> VC shop follows Y Combinator into the world of biotech incubators. Article

Animal Health News

> Chronic wasting disease found in Iowa captive deer population. Item

> U.K.'s Pirbright Institute tabbed for $29M in funding to train vet scientists. More

> Pan Genome Systems searching for money to fund new Johne's disease vaccine. Article

> UC Davis researchers solve century-old bluetongue virus mystery. Story

> Three European companies will team to develop VLP vaccines for vet use. Report

And Finally... Frozen fecal matter that's swallowed like a pill appears effective against C. difficile, a recurring and sometimes deadly bacterial infection, a new study says. More

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.